This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.
Endocrine oncology (Bristol, England) · 2026
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
European urology · 2026
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.
The Journal of urology · 2025
Latest funding
- $1,005,976
Defining circulating tumor DNA kinetics as a treatment response biomarker in metastatic prostate cancer
CIHR · 2025 · Principal investigator
- $2,487,015
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
CIHR · 2024 · Co-investigator
- $841,500
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
CIHR · 2021 · Co-investigator
37 publications.
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.
Gorman M, Usmani N, Pollak MN, Ghosh S, Elangovan A, Kim J, Thoms J, Bouchard M, Peacock M, Wang Y, Fleshner NE, Campbell H, Vigneault E, Vincent F, So A, Cury FL, Quon HC, Carlson RG, Lambert C, Klotz L, Chi K, Brundage M, Courneya KS, Eigl BJ
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
Riaz IB, Ahmed Naqvi SA, Faisal KS, He H, Rubab Khakwani KZ, Childs DS, Orme JJ, Ravi P, Singh P, Hussain SA, Chi K, Agarwal N, Merseburger AS, Davis ID, Armstrong A, Hussain MH, Smith M, Attard G, Tombal B, Fizazi K, James N, Omlin A, Gillessen S, Murad MH, Van Allen EM, Sweeney CJ, Bryce AH
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.
Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, Peacock M, Fleshner N, Campbell H, Vigneault E, Vincent F, So A, Cury F, Quon H, Carlson R, Lambert C, Klotz L, Chi K, Brundage M, Pollak M, Rebane L, Chiu L, Courneya KS, Usmani N
Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
Machine Learning Model Integrating Computed Tomography Image-Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer.
Ozgun G, Abdalvand N, Ozcan G, Nip KM, Khazamipour N, Rahmim A, Bell R, MauriceDror C, Soleimani M, Chi K, Eigl BJ, Nichols C, Kollmannsberger C, Yuan R, Nappi L
Reply by Authors.
Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, Peacock M, Fleshner N, Campbell H, Vigneault E, Vincent F, So A, Cury F, Quon H, Carlson R, Lambert C, Klotz L, Chi K, Brundage M, Pollak M, Rebane L, Chiu L, Courneya KS, Usmani N
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.
Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G, Maurice-Dror C, Eigl B, Chi K, Kollmannsberger C, Nappi L
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)
So AI, Chi K, Danielson B, Fleshner N, Kinnaird A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar SS
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
Defining circulating tumor DNA kinetics as a treatment response biomarker in metastatic prostate cancer
Principal investigators: Wyatt, Alexander W; Chi, Kim N
Keywords: Biomarker; Cancer Genomics; Ctdna; Liquid Biopsy; Prostate Cancer; Treatment Resistance
TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors (ARPI) and Androgen Deprivation Treatment (ADT) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response.
Principal investigators: Ong, Michael; Jafri, mariam
Keywords: Androgen Deprivation Treatment (Adt); Androgen Receptor Pathway Inhibitors (Arpi); Circulating Tumour Dna (Ctdna); Docetaxel; International; Metastatic Castration-Sensitive Prostate Cancer; Prostate Specific Antigen (Psa); Randomized Controlled Trial
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
Principal investigators: Wyatt, Alexander W; Eigl, Bernhard J
Keywords: Bladder Cancer; Cancer Genomics; Circulating Tumour Dna (Ctdna); Clinical Outcomes; Metastatic Progression; Treatment Resistance
Genomic dissection of de novo metastatic prostate cancer prior to treatment
Principal investigators: Wyatt, Alexander W; Chi, Kim N; Ost, Piet
Keywords: Cancer Genomics; Circulating Tumour Dna (Ctdna); Metastatic Progression; Prostate Cancer
Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA
Principal investigators: Wyatt, Alexander W; Chi, Kim N
Keywords: Ctdna; Dna Sequencing; Liquid Biopsy; Plasma Cell-Free Dna; Prognosis
Development of Technologies for Rapid Isolation and Genome Sequencing of Single Circulating Tumor Cells in Prostate Cancer
Principal investigators: Ma, Hongshen; Wyatt, Alexander W
Keywords: Biomarkers; Castrate Resistant Prostate Cancer; Cell-Free Dna; Circulating Tumor Cells; Genome Sequencing; Liquid Biopsy; Metastasis; Microfluidics; Prostate Cancer; Single Cell
Microfluidic Separation of Circulating Tumor Cells
Principal investigators: Ma, Hongshen
Keywords: Biomechanics; Circulating Tumor Cells; Deformability; Lab-On-A-Chip; Medical Device; Microfluidics; Prostate Cancer
A virus-based strategy for measurement of circulating tumour cells
Principal investigators: Rennie, Paul S
Keywords: Castration-Resistant; Circulating Tumour Cells; Metastases; Oncolytic Virus; Prostate Cancer; Targeting
Relational autonomy and decision making: Improving clinical trial enrolment in cancer care.
Principal investigators: Balneaves, Lynda G
Keywords: Autonomy; Cancer; Clinical Trials; Decision Making; Feminist Critical Theory; Grounded Theory; Relational Autonomy; Research Ethics
The Terry Fox New Frontiers Program on Prostate Cancer Progression (M. Gleave)
Principal investigators: Gleave, Martin E; Chi, Kim N; Collins, Colin C; Cox, Michael E; Guns, Emma S; Ong, Christopher J; Rennie, Paul S; Wang, Yuzhuo
Keywords: Genomic Markers; Prostate Cancer; Targeted Therapies; Translational Research
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Urologic Sciences
- Oncology
- Surgery
- Cancer Care and Epidemiology
- Electrical and Computer Engineering
- Clinical Pharmacology
- Molecular Oncology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Martin Gleave
Urologic Sciences
7 shared papers, latest 2021
Lucia Nappi
Urologic Sciences
6 shared papers, latest 2025
Eric Vigneault
Faculty
5 shared papers, latest 2026
Alan So
Urologic Sciences
5 shared papers, latest 2026
Sebastien Hotte
Oncology
4 shared papers, latest 2025
Bobby Shayegan
Surgery
4 shared papers, latest 2025
Michael Brundage
Cancer Care and Epidemiology
3 shared papers, latest 2026
Scott Tyldesley
Faculty
3 shared papers, latest 2019
Christina Canil
Faculty
3 shared papers, latest 2025
Neil Fleshner
Faculty
3 shared papers, latest 2025
Nawaid Usmani
Electrical and Computer Engineering
3 shared papers, latest 2026
Michael Peacock
Faculty
3 shared papers, latest 2026
Eric Winquist
Clinical Pharmacology
2 shared papers, latest 2025
Bernhard Eigl
Urologic Sciences
2 shared papers, latest 2025
Lesley Seymour
Faculty
2 shared papers, latest 2025
Michael Ong
Faculty
2 shared papers, latest 2025
Amina Zoubeidi
Urologic Sciences
2 shared papers, latest 2013
Aly-Khan Lalani
Oncology
2 shared papers, latest 2025
Michael Pollak
Oncology
2 shared papers, latest 2025
Urban Emmenegger
Faculty
1 shared papers, latest 2025
Michael Mckenzie
Audiology and Speech Science
1 shared papers, latest 2019
Arman Rahmim
Faculty
1 shared papers, latest 2025
Michael Kolinsky
Oncology
1 shared papers, latest 2021
Krista Noonan
Urologic Sciences
1 shared papers, latest 2021
Srikala Sridhar
Faculty
1 shared papers, latest 2025
Ilias Cagiannos
Faculty
1 shared papers, latest 2021
David Huntsman
Molecular Oncology
1 shared papers, latest 2019
Gregory Pond
Oncology
1 shared papers, latest 2018
Ming-Sound Tsao
Department of Laboratory Medicine and Pathobiology
1 shared papers, latest 2025
Antonio Finelli
Faculty
1 shared papers, latest 2021
Julian Kim
Radiology
1 shared papers, latest 2026
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.